Daxor’s (DXR) “Neutral” Rating Reiterated at Roth Capital

Daxor (NYSEAMERICAN:DXR)‘s stock had its “neutral” rating restated by Roth Capital in a report released on Monday, TipRanks reports. They presently have a $18.00 target price on the stock. Roth Capital’s price objective indicates a potential upside of 101.39% from the stock’s previous close.

Separately, Maxim Group started coverage on Daxor in a research note on Monday, July 29th. They set a “buy” rating and a $22.00 price target for the company.

Shares of DXR stock traded down $0.11 during trading hours on Monday, hitting $8.94. The stock had a trading volume of 763 shares, compared to its average volume of 25,621. Daxor has a twelve month low of $4.52 and a twelve month high of $19.95.

About Daxor

Daxor Corporation, a medical device company, provides biotechnology and cryobanking services in the United States. The company offers BVA-100 Blood Volume Analyzer, an instrument that measures blood volume in human body. BVA-100 Blood Volume Analyzer is used to diagnose and treat patients in various medical and surgical conditions, including congestive heart failure, critical care medicine and intensive care unit medicine, hypertension, syncope, pre-operative blood screening for hidden anemia, anemia in cancer patients, kidney failure, and hyponatremia.

Featured Article: How is Preferred Stock Different from Common Stock?

Receive News & Ratings for Daxor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daxor and related companies with MarketBeat.com's FREE daily email newsletter.